Levamisole and 5-fluorouracil therapy for resected colon cancer

A new indication

J. R. Skillings, M. Levine, H. L. Rayner, E. Eisenhauer, C. Erlichman, C. Germond, I. Kerr, W. Lofters, J. Maroun, S. Yoshida

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: To evaluate the benefits and risks of postoperative treatment with levamisole plus 5-fluorouracil (5-FU) in patients with colon cancer. Design: Computerized searches of MEDLINE and CANCERLIT were performed, and the reference list of each retrieved article was checked. Only randomized trials of therapy with levamisole alone or combined with 5-FU for colon cancer without distant metastases were included. The studies were then evaluated with the use of four criteria. Results: We reviewed six randomized trials, of which three satisfied our criteria. Two studies demonstrated a significant improvement in the survival rate with levamisole plus 5-FU among patients with colon cancer and pathologically confirmed metastases to adjacent lymph nodes (Dukes' stage C). A subgroup analysis in another study demonstrated a similar benefit. The toxic effects of the drugs were generally mild. The three other studies showed no difference in survival rates between the treatment groups; however, the samples were too small to detect a clinically or statistically important difference. Conclusions: Because many patients with colon cancer will suffer a relapse we recommend that they be offered the opportunity to participate in clinical trials of adjuvant therapy. For those with stage C disease not entering a clinical trial levamisole plus 5-FU is appropriate adjuvant therapy.

Original languageEnglish (US)
Pages (from-to)297-301
Number of pages5
JournalCMAJ
Volume144
Issue number3
StatePublished - 1991
Externally publishedYes

Fingerprint

Levamisole
Fluorouracil
Colonic Neoplasms
Survival Rate
Clinical Trials
Neoplasm Metastasis
Therapeutics
Poisons
MEDLINE
Lymph Nodes
Recurrence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Skillings, J. R., Levine, M., Rayner, H. L., Eisenhauer, E., Erlichman, C., Germond, C., ... Yoshida, S. (1991). Levamisole and 5-fluorouracil therapy for resected colon cancer: A new indication. CMAJ, 144(3), 297-301.

Levamisole and 5-fluorouracil therapy for resected colon cancer : A new indication. / Skillings, J. R.; Levine, M.; Rayner, H. L.; Eisenhauer, E.; Erlichman, C.; Germond, C.; Kerr, I.; Lofters, W.; Maroun, J.; Yoshida, S.

In: CMAJ, Vol. 144, No. 3, 1991, p. 297-301.

Research output: Contribution to journalArticle

Skillings, JR, Levine, M, Rayner, HL, Eisenhauer, E, Erlichman, C, Germond, C, Kerr, I, Lofters, W, Maroun, J & Yoshida, S 1991, 'Levamisole and 5-fluorouracil therapy for resected colon cancer: A new indication', CMAJ, vol. 144, no. 3, pp. 297-301.
Skillings JR, Levine M, Rayner HL, Eisenhauer E, Erlichman C, Germond C et al. Levamisole and 5-fluorouracil therapy for resected colon cancer: A new indication. CMAJ. 1991;144(3):297-301.
Skillings, J. R. ; Levine, M. ; Rayner, H. L. ; Eisenhauer, E. ; Erlichman, C. ; Germond, C. ; Kerr, I. ; Lofters, W. ; Maroun, J. ; Yoshida, S. / Levamisole and 5-fluorouracil therapy for resected colon cancer : A new indication. In: CMAJ. 1991 ; Vol. 144, No. 3. pp. 297-301.
@article{6add3f03916c4bdfafab8de979e794af,
title = "Levamisole and 5-fluorouracil therapy for resected colon cancer: A new indication",
abstract = "Objective: To evaluate the benefits and risks of postoperative treatment with levamisole plus 5-fluorouracil (5-FU) in patients with colon cancer. Design: Computerized searches of MEDLINE and CANCERLIT were performed, and the reference list of each retrieved article was checked. Only randomized trials of therapy with levamisole alone or combined with 5-FU for colon cancer without distant metastases were included. The studies were then evaluated with the use of four criteria. Results: We reviewed six randomized trials, of which three satisfied our criteria. Two studies demonstrated a significant improvement in the survival rate with levamisole plus 5-FU among patients with colon cancer and pathologically confirmed metastases to adjacent lymph nodes (Dukes' stage C). A subgroup analysis in another study demonstrated a similar benefit. The toxic effects of the drugs were generally mild. The three other studies showed no difference in survival rates between the treatment groups; however, the samples were too small to detect a clinically or statistically important difference. Conclusions: Because many patients with colon cancer will suffer a relapse we recommend that they be offered the opportunity to participate in clinical trials of adjuvant therapy. For those with stage C disease not entering a clinical trial levamisole plus 5-FU is appropriate adjuvant therapy.",
author = "Skillings, {J. R.} and M. Levine and Rayner, {H. L.} and E. Eisenhauer and C. Erlichman and C. Germond and I. Kerr and W. Lofters and J. Maroun and S. Yoshida",
year = "1991",
language = "English (US)",
volume = "144",
pages = "297--301",
journal = "Canadian Medical Association Journal",
issn = "0008-4409",
publisher = "Canadian Medical Association",
number = "3",

}

TY - JOUR

T1 - Levamisole and 5-fluorouracil therapy for resected colon cancer

T2 - A new indication

AU - Skillings, J. R.

AU - Levine, M.

AU - Rayner, H. L.

AU - Eisenhauer, E.

AU - Erlichman, C.

AU - Germond, C.

AU - Kerr, I.

AU - Lofters, W.

AU - Maroun, J.

AU - Yoshida, S.

PY - 1991

Y1 - 1991

N2 - Objective: To evaluate the benefits and risks of postoperative treatment with levamisole plus 5-fluorouracil (5-FU) in patients with colon cancer. Design: Computerized searches of MEDLINE and CANCERLIT were performed, and the reference list of each retrieved article was checked. Only randomized trials of therapy with levamisole alone or combined with 5-FU for colon cancer without distant metastases were included. The studies were then evaluated with the use of four criteria. Results: We reviewed six randomized trials, of which three satisfied our criteria. Two studies demonstrated a significant improvement in the survival rate with levamisole plus 5-FU among patients with colon cancer and pathologically confirmed metastases to adjacent lymph nodes (Dukes' stage C). A subgroup analysis in another study demonstrated a similar benefit. The toxic effects of the drugs were generally mild. The three other studies showed no difference in survival rates between the treatment groups; however, the samples were too small to detect a clinically or statistically important difference. Conclusions: Because many patients with colon cancer will suffer a relapse we recommend that they be offered the opportunity to participate in clinical trials of adjuvant therapy. For those with stage C disease not entering a clinical trial levamisole plus 5-FU is appropriate adjuvant therapy.

AB - Objective: To evaluate the benefits and risks of postoperative treatment with levamisole plus 5-fluorouracil (5-FU) in patients with colon cancer. Design: Computerized searches of MEDLINE and CANCERLIT were performed, and the reference list of each retrieved article was checked. Only randomized trials of therapy with levamisole alone or combined with 5-FU for colon cancer without distant metastases were included. The studies were then evaluated with the use of four criteria. Results: We reviewed six randomized trials, of which three satisfied our criteria. Two studies demonstrated a significant improvement in the survival rate with levamisole plus 5-FU among patients with colon cancer and pathologically confirmed metastases to adjacent lymph nodes (Dukes' stage C). A subgroup analysis in another study demonstrated a similar benefit. The toxic effects of the drugs were generally mild. The three other studies showed no difference in survival rates between the treatment groups; however, the samples were too small to detect a clinically or statistically important difference. Conclusions: Because many patients with colon cancer will suffer a relapse we recommend that they be offered the opportunity to participate in clinical trials of adjuvant therapy. For those with stage C disease not entering a clinical trial levamisole plus 5-FU is appropriate adjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025974680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025974680&partnerID=8YFLogxK

M3 - Article

VL - 144

SP - 297

EP - 301

JO - Canadian Medical Association Journal

JF - Canadian Medical Association Journal

SN - 0008-4409

IS - 3

ER -